modelEthylHydroxybenzoate
Extends from Pharmacolibrary.Drugs.ATC.D.D01AE10.
Information
| name: | EthylHydroxybenzoate | |
| ATC code: | D01AE10 | route: | oral |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.5 | L |
| clearance: | 5 | L/h |
| other parameters in model implementation | ||
Ethyl hydroxybenzoate, also known as ethylparaben, is a paraben-class preservative with antifungal and antibacterial properties, commonly used in cosmetics, pharmaceuticals, and food products to prevent microbial growth. It is sometimes used topically for dermatological applications due to its antifungal effects (ATC code D01AE10), but is not a primary therapeutic drug and is not approved for systemic use as a medicine.
Pharmacokinetics
No published pharmacokinetic studies in humans are available for ethyl hydroxybenzoate itself. The following parameters are broad estimates based on chemical similarity to other parabens (such as methylparaben and propylparaben) and limited reports of rapid absorption and elimination after oral or topical administration in animal models and indirect human exposure studies.
References
Bury, D, et al., & Koch, HM (2019). Urinary metabolites of the UV filter 2-Ethylhexyl salicylate as biomarkers of exposure in humans. Toxicology letters 309 35–41. DOI:10.1016/j.toxlet.2019.04.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30953687
Yan, M, et al., & Zhu, YG (2010). Determination of metoclopramide in human plasma by LC-ESI-MS and its application to bioequivalance studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 878(11-12) 883–887. DOI:10.1016/j.jchromb.2010.02.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20189472
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)